Abstract
Lung cancer is the commonest cause of cancer-related mortality worldwide.
Surgery is the mainstay of curative therapy for early stage non-small cell lung
cancer (NSCLC) with or without adjuvant chemotherapy to reduce risk of relapse.
For inoperable locally advanced NSCLC, and for small cell lung cancer (SCLC)
limited to the thorax, chemoradiotherapy is given with curative intent. However, the majority of patients have disseminated, metastatic disease at presentation and palliative chemotherapy with the aims of improving symptoms, optimising quality of life and extending survival may be appropriate.
A platinum drug, often in combination, is the mainstay of both curative intent and palliative chemotherapy for SCLC and NSCLC. Recently, epidermal growth factor receptor (EGFR) inhibitors have been licensed for use in NSCLC. This chapter will focus on these new agents and how molecular profiling on EGFR and KRAS mutation is informative in selecting patients most likely to respond.
Surgery is the mainstay of curative therapy for early stage non-small cell lung
cancer (NSCLC) with or without adjuvant chemotherapy to reduce risk of relapse.
For inoperable locally advanced NSCLC, and for small cell lung cancer (SCLC)
limited to the thorax, chemoradiotherapy is given with curative intent. However, the majority of patients have disseminated, metastatic disease at presentation and palliative chemotherapy with the aims of improving symptoms, optimising quality of life and extending survival may be appropriate.
A platinum drug, often in combination, is the mainstay of both curative intent and palliative chemotherapy for SCLC and NSCLC. Recently, epidermal growth factor receptor (EGFR) inhibitors have been licensed for use in NSCLC. This chapter will focus on these new agents and how molecular profiling on EGFR and KRAS mutation is informative in selecting patients most likely to respond.
| Original language | English |
|---|---|
| Title of host publication | Pharmacogenetics: |
| Subtitle of host publication | Making cancer treatment safer and more effective |
| Editors | William G. Newman |
| Publisher | Springer Nature |
| Pages | 87-99 |
| Number of pages | 12 |
| ISBN (Electronic) | 978-90-481-8618-1 |
| ISBN (Print) | 978-90-481-8618-1 |
| Publication status | Published - 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Highlights, Institutes and Platforms
- Manchester Cancer Research Centre
Fingerprint
Dive into the research topics of 'Pharmacogenetics in Lung Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver